

**Register Early
for Maximum Savings**

30th
International



BIODETECTION TECHNOLOGIES

VIRTUAL

JUNE 7-8, 2023 EDT [UT-4:00]

**FEATURED
SPEAKERS**

Advanced Technologies & Methods for Global Health & Biodefense



Asha George, PhD
*Executive Director
Bipartisan Commission on
Biodefense*




Cory Bernhards, PhD
*Research Biologist
DEVCOM Chemical
Biological Center*



**Shanmuga
Sozhamannan, PhD**
*Technical Coordinator, Joint Project Lead,
Joint Program Executive Office
Defense Biological Product Assurance
Office*



Harshini Mukundan, PhD
*Scientist and Program Manager
Lawrence Berkeley National
Laboratory; Senior Policy Advisor
The Council on Strategic Risks*



Matthew T. Quinn
*Senior Advisor
Health Resources & Services
Administration*

BiodetectionTechnologies.com

Organized by:





BIODETECTION TECHNOLOGIES

VIRTUAL

About the Event

Your Go-To Biodetection Technologies Meeting to Hear the Latest Developments to Stop Biothreats

We hope you will join us at the **30th International Biodetection Technologies** virtual conference on June 7-8, 2023. This internationally recognized meeting is for experts in detection & identification of biological threats. This 2-part event will address the key topics in detection and present the latest R&D and technological innovation in ready-to-market systems. In addition, this meeting focuses on the latest strategies to overcome the hurdles to the identification of global biological threats and translational gaps in bringing technologies from lab to field. **This conference will livestream on Eastern Daylight Time (EDT).**

8:00 AM
- 5:00 PM

6:00 PM
- 7:30 PM

DAY 1

TUESDAY, JUNE 7, 2023

VIRTUAL (EASTERN DAYLIGHT TIME)

DAY 2

WEDNESDAY, JUNE 8, 2023

VIRTUAL (EASTERN DAYLIGHT TIME)



30TH INTERNATIONAL
**BIOTHREAT &
PATHOGEN DETECTION**

Advanced Technologies for
Detection, Diagnostics and
Analytics



30TH INTERNATIONAL
**POINT-OF-CARE
DIAGNOSTICS
FOR GLOBAL HEALTH
& BIODEFENSE**

Advanced Methods to Enable
Critical Decision-Making



Short Course
**SAMPLE PREP
TECHNOLOGIES**



#Biodetection23

Connect from anywhere.

Join via our robust virtual platform and access these dynamic features.

Presented in

 **BigMarker**

INTUITIVE
INTERFACE



COMPANY
BRANDING



INTERACTIVE
DISCUSSIONS



DOWNLOADS



LIVE CHAT



LIVE
SESSIONS



RECORDED
SESSIONS



POSTER
SESSIONS



SPONSORSHIP & LEAD GENERATION OPPORTUNITIES

PREMIER SPONSOR (LIMITED AVAILABILITY)

- 30-Minute Presentation
- Pre & Post Email Blast to all attendees
- Post event, CHI will provide full contact information (GDPR compliant) for your specific session and the full conference attendee list
- and much MORE!

CORPORATE SPONSORSHIP PRESENTATION

- 15-Minute Presentation
- Post event, CHI will provide full contact information for your specific session
- and much MORE!

CORPORATE SUPPORT SPONSOR

- 5-minute Technology Showcase
- Corporate logo placed on conference materials
- and MORE

PAST SPONSORS


- | | | |
|-----------------------|--|--------------------------------|
| • Air Techniques Intl | • Homeland Defense & Security Information Analysis Ctr | • Meso Scale Diagnostics |
| • Beaufort CRO | • InnovaPrep | • Norgen Biotek Corp |
| • Cellmic LLC | • Integrated Nano Technologies LLC | • Oxford Nanopore Technologies |
| • Co Diagnostics Inc | • List Biological Labs | • Roche Applied Science |
| • Copan Italia SpA | • Longhorn Vaccines & Diagnostics LLC | • SteraMist |
| • DNA Script | | • T2 Biosystems |
| • FBI | | • TetraCore Inc |

LOOKING FOR ADDITIONAL WAYS TO DRIVE LEADS TO YOUR SALES TEAM?

CHI's Lead Generation Programs will help you obtain more targeted, quality leads throughout the year. We will mine our database of 800,000+ life science professionals to your specific needs. We guarantee a minimum of 100 leads per program! Opportunities include:


- Live Webinars
- White Papers
- Market Surveys
- Podcasts and More

PAST CONFERENCE DEMOGRAPHICS




COMPANY TYPE

Biotech	39%
Government	32%
Academic	14%
Healthcare	6%
Services	4%
Societies	3%
Pharma	2%



GEOGRAPHIC LOCATION

USA	90%
East Coast	56%
Midwest	25%
West Coast	19%
Asia	6%
Europe	4%



DELEGATE TITLE

Executive	20%
Director	10%
Manager	14%
Professor	4%
Scientist/Technologist	42%
Sales & Marketing	8%
Other	2%

Contact Us For more information regarding sponsorship opportunities, please contact:

Jon Stroup

Senior Business Development Manager
781-972-5483
jstroup@healthtech.com





30TH INTERNATIONAL

BIOTHREAT AND PATHOGEN DETECTION

Advanced Technologies for Detection, Diagnostics and Analytics

WEDNESDAY, JUNE 7, 2023

The COVID-19 pandemic has exposed everyone to the results of a lack of funded preparedness. As emerging pathogens increasingly jump from animals to humans, the number of outbreaks grow – and it is critical to learn from the mistakes of this pandemic and prepare for the next coming threats. The 30th International Biothreat & Pathogen Detection is an internationally recognized meeting for experts in detection & identification of biological threats. This conference will address the key topics in pathogen detection and present the latest R&D and technological innovation in ready-to-market systems. In addition, this meeting will focus on the latest strategies to overcome the hurdles to the identification of global biological threats and translational gaps in bringing technologies from lab to field. This conference will feature stimulating discussions, perspectives of end users, high quality case studies, and provide the opportunity to network with the leading experts in detection from around the globe. **This virtual conference will livestream on Eastern Daylight Time (EDT).**

WEDNESDAY, JUNE 7

8:55 am Chairperson's Opening Remarks

Craig Wohlers, Executive Director, Conferences, Cambridge Healthtech Institute

OVERCOMING THE HURDLES TO EFFECTIVE POLICY IMPLEMENTATION FOR BIODEFENSE

9:00 FEATURED PRESENTATION: A National Blueprint for Biodefense: Leadership and Major Reform Still Needed to Advance Efforts

Asha George, PhD, Executive Director, Bipartisan Commission on Biodefense

In 2015, the Bipartisan Commission on Biodefense released its foundational National Blueprint for Biodefense. At the time, the Commission deemed the United States dangerously vulnerable to biological events. By 2023, large-scale biological events have forced some changes to our national and global biodefense, but gaps and inadequacies remain. We must continue to prepare for future pandemics, even as we recover from COVID-19 and respond to the spread of other diseases.

ADVANCED METHODS FOR BIODETECTION



9:30 KEYNOTE PRESENTATION: Innovating Diagnostics to End a Pandemic: The RADx Tech Experience

Steven Schachter, MD, Professor, Neurology, Harvard Medical School; Chief Academic Officer and RADx

Chief, CIMIT

Rapid Acceleration of Diagnostics (RADx) Tech is an NIH-funded program to accelerate development, validation, and commercialization of innovative point-of-care and home-based tests, as well as improvements to clinical laboratory tests, that can directly detect the virus that causes COVID-19 and its variants. The program generated 27 FDA Emergency Use Authorizations for COVID-19 diagnostic tests, including the first over-the-counter test for use at home without prescription, and produced 500 million tests.

10:00 Nanopore Sequencing for Biothreat Detection and Characterization

Cory Bernhards, PhD, Research Biologist, DEVCOM Chemical Biological Center

Nanopore sequencing technology has enabled numerous applications for rapidly identifying and characterizing biological threats. Warfighters are being trained to execute these protocols, which will revolutionize biothreat detection in the field. Methods for sample/library preparation are being further simplified/automated for use by non-laboratory trained operators, and bioinformatics software was designed to automatically identify biothreats in real-time. In addition, protocols have been used to monitor for SARS-CoV-2 variants among warfighter populations.

10:30 Session Break

11:00 Detecting Biothreats at U.S. Borders

John Sagle, Deputy Executive Director, Agriculture Programs and Trade Liaison, Office of Field Operations, U.S. Customs and Border Protection

U.S. Customs and Border Protection (CBP), a federal border control and management agency, is charged with anticipating, detecting, and disrupting terrorism threats, including biothreats, to protect the people and economy of the United States. CBP has developed specialized resources to counteract biothreats and employs robust outreach efforts for private industry, academic institutions, and external stakeholders to increase biological related material, data, and sensitive technology compliance.

11:30 Pushing the Boundaries: Assessing the Impact of Mutations in SARS-CoV-2 on the Performance of Molecular Diagnostic Tests

Shanmuga Sozhamannan, PhD, Technical Coordinator, Joint Project Lead, Joint Program Executive Office, Defense Biological Product Assurance Office

Wet lab testing data of the *in silico* predictions of SARS-CoV-2 assay failures due to mismatches in assay signatures will be discussed. We found the majority of assays with mismatches in primer/probe regions performed without drastic degradation in assay performance. We identified critical nucleotides, positions, and types of changes that may impact assay performance. These data can be used to improve *in silico* predictions by our PCR Signature Erosion Tool.



12:00 pm Rapid and Automated Identification of Aerosolized Biothreats

Vishaka Santosh, PhD, Senior Research Scientist, DEVCOM Chemical Biological Center, Aberdeen Proving Ground

Available methods for biological aerosol collection and identification are slow and require manual intervention. In order to achieve rapid, automated, and unmanned identification of aerosolized biothreats, we have developed a portable low-cost prototype that couples a customized microwell aerosol collector with an automated elution module and conducts fully-automated sample preparation and loop-mediated isothermal amplification (LAMP) analysis for rapid and accurate biothreat identification.

12:30 Sponsored Presentation (Opportunity Available)

1:00 Session Break

RAPID AND FUTURE TECHNOLOGIES FOR BIODETECTION

1:40 Chairperson's Remarks

Cory Bernhards, PhD, Research Biologist, DEVCOM Chemical Biological Center

1:45 Rapid Detection of Biological Toxins in the Field

Andrew R. Flannery, PhD, Chief Scientist, Biotechnology, Smiths Detection

Protein toxins provide unique challenges for identification and cannot be directly detected by molecular assays. In order to overcome these issues, Smiths Detection has developed a rapid immuno-based assay based on CANARY technology and capable of detecting plant-derived toxins such as ricin or abrin, and bacterial toxins such as Botulinum neurotoxin or Shiga toxin. This talk will review data from laboratory testing and present a new solution for field testing.

2:15 Novel Tools for Detection of Emerging Zoonotic Pathogens

Neeraja Venkateswaran, PhD, Senior Scientist, R&D, Tetracore, Inc.

The increased frequency of international movement of the human and animal population can potentially lead to a rapid spread of the emerging zoonotic pathogens. Early detection is vital for developing a comprehensive approach to contain outbreaks of zoonotic pathogens. Here I will discuss sensitive detection tools and efficient sampling strategies for surveillance studies.

2:45 Large-Area Microbial Surface Sampling

Dave Alburty, CEO, InnovaPrep

Microbial surface sampling of relatively large surface areas from 1-10 square meters is needed to drive relevant data collection in real-world environments. Successful methods efficiently

sample from such areas and deliver final samples with a small liquid volume for use with RMMs and sequencing techniques. Methods developed by NASA for use in cleanrooms and in space environments will be discussed along with a single-handed sponge-in-bag sampler developed for DoD.

3:15 Ultrasensitive Rapid Pathogen Detection Platform Using Quasi-Freestanding Epitaxial Graphene

Kevin Daniels, PhD, Assistant Professor of Electrical and Computer Engineering, University of Maryland

A novel quasi-freestanding epitaxial graphene (QEG) biosensor is presented, capable of electrically transducing biological bindings in seconds. A sensing mechanism unique to QEG, polarization-induced strain, due to the interplay of polarization fields generated by the underlying hydrogen-terminated silicon carbide substrate and the crosslinker, poly-L-lysine (PLL) functionalization, was observed, revealing unprecedented sensitivity and detection speeds. The sensor has demonstrated the detection of as little as 60 copies/mL of SARS-CoV-2 in seconds.

3:45 Session Break

4:15 RIGEL: A Genomic-Based Enterprise for Unknown Pathogen Characterization

Willy Valdivia-Granda, Founder & CEO, Orion Integrated Biosciences, Inc.

The analysis of genomic data continues to be at the centerpiece of several detection and characterization efforts. Here we introduce different examples of microbial detection in terrestrial and aquatic environments using a set of complex biological matrices. The implications of this biodetection approach in the development of the biosurveillance and biodefense enterprise will be discussed.

4:45 PANEL DISCUSSION: Market Demand and Overcoming the Barriers to Commercialization for the Next-Generation Device Development

Moderator: Cory Bernhards, PhD, Research Biologist, DEVCOM Chemical Biological Center

This panel discussion will examine the device development cycle from identifying the need in the marketplace to developing the technology and the strategies for implementation. Our panel of experts will discuss how best to navigate the obstacles to bridging the valley of death between R&D and advanced development to ensure successful device commercialization.

5:45 Session Break

6:00 Short Course 1: Sample Prep Technologies*

*Separate registration is required. See Short Course page for details.

7:30 Close of Day 1



30TH INTERNATIONAL

POINT-OF-CARE DIAGNOSTICS FOR GLOBAL HEALTH & BIODEFENSE

Advanced Methods to Enable Critical Decision-Making

THURSDAY, JUNE 8, 2023

Public health emergencies caused by infectious disease, such as COVID-19, have the potential to kill hundreds of thousands of people. The development of bioanalytical methods that are field-ready, compatible, scalable, and reliable is critical to effective diagnostics at the point-of-care. In addition, clinical data must be generated and incorporated into the key operational decision-maker networks. The 30th International Point-of-Care Diagnostics for Global Health & Biodefense brings together the international industry, academic, and government biodetection community to discuss advancements in approaches for optimizing performance of field technologies, translational challenges, diagnostic tools, and data analysis to enable effective decision-making. **This virtual conference will livestream on Eastern Daylight Time (EDT).**

THURSDAY, JUNE 8

ADVANCES IN FIELDABLE TECHNOLOGIES AND ASSAYS

8:55 am Chairperson's Opening Remarks

Craig Wohlers, Executive Director, Conferences, Cambridge Healthtech Institute

9:00 Agnostic Diagnostics to Combat the Next Emerging Outbreak

Harshini Mukundan, PhD, Scientist and Program Manager, Lawrence Berkeley National Laboratory; Senior Policy Advisor, The Council on Strategic Risks

There is a clear and imminent need for diagnostics and broad spectrum therapeutics to minimize the impact of emerging threats. Our team has been working on developing such tools, using the innate immune system as an inspiration for the development of the approach. The diagnostic strategies, and the applications to bacterial and viral pathogens will be discussed.

9:30 Pathogen Detection via Fluorogenic Substrates for Nuclease Biomarkers

James McNamara, PhD, Scientific Founder & CEO, Nuclease Probe Technologies

The greater abundance of proteins vs. nucleic acids provides an important sensitivity advantage for pathogen detection methods that target protein biomarkers. Nucleases are a ubiquitous category of enzymes that can serve as protein biomarkers and can be detected via their activation of fluorogenic oligonucleotide substrates. This talk will provide an overview of a nuclease-detection technology platform we have developed to detect various pathogens and also describe some point-of-care applications.

10:00 Environmental Exposure to Microplastics and Their Effect on Coagulation

Nathan Alves, PhD, Assistant Professor/Director of Translational Research, Emergency Medicine, Indiana University School of Medicine

Microplastics that have been manufactured or created through environmental degradation can enter the body through ingestion, inhalation, or transdermal pathways. To investigate the effects of nanoplastics on clot formation, an *ex vivo* human thrombin/fibrinogen model was utilized. Polystyrene particles (100nm; non-functionalized [nPS] and aminated [aPS]) were preincubated at 0-200 µg/mL with thrombin or fibrinogen and clot formation was characterized via turbidity (405nm) and thromboelastography (TEG) to determine effects on thrombosis/hemostasis.

10:30 Session Break

NEXT-GENERATION TOOLS AND TECHNOLOGY AT THE POINT-OF-CARE

11:00 Medical Device Autonomy and Data Interoperability in Support of Multi-Domain Operations (MDO) and Disaster Environments

Matthew T. Quinn, Senior Advisor, Health Technology, Health Resources & Services Administration

Autonomous medical devices can support Multi-Domain Operations (MDO) and disaster medical to expand care capability and capacity for large numbers of casualties/patients using fewer human resources. The presentation will describe live, scenario-based use of these tools and technologies in support of next-generation medical care and the opportunities afforded by such technologies and new care models.

11:30 100% SARS-CoV-2 Genome Detection in Saliva-Free Distal Airway Fraction Exhaled Breath

Stergios Moschos, PhD, Associate Professor in Cellular and Molecular Sciences, Northumbria University

Breath-based respiratory pathogen detection has been hotly pursued especially during COVID-19. Most solutions collect/measure salivary virus load, or non-specific biomarkers. We present a breath collector that isolates and condenses the distal airway fraction of exhaled breath that yields quantifiable SARS-CoV-2 genomes and host biomarkers in 1 min sample, whilst eliminating virus infectivity.

12:00 pm Who's Afraid of the Monkeypox Virus?

David Ussery, PhD, Director ArC GEM & Professor, Biomedical Informatics, University of Arkansas for Medical Sciences

The monkeypox virus (MPXV) has recently spread outside of Africa, and the 2022 human monkeypox (hMPXV) outbreak has most reported cases in Europe and North America. We are developing wastewater monitoring systems to detect and fully sequence all orthopox viruses, including hMPXV. MPXV has been successfully and consistently detected in wastewater at low levels, and so far all of the viral genomes belong to the same clade, with little variation.

12:30 Sponsored Presentation (Opportunity Available)

1:00 Session Break

OPTIMIZING PERFORMANCE OF TRADITIONAL POINT-OF-CARE DETECTION

1:55 Chairperson's Remarks

Craig Wohlers, Executive Director, Conferences, Cambridge Healthtech Institute



2:00 New Resources to Assist Developers of Point-of-Care Tests for Infectious Diseases

Joany Jackman, PhD, Senior Scientist, Research & Exploratory Development, Johns Hopkins University

The Johns Hopkins University Applied Physics Laboratory (JHU/APL) is part of the Johns Hopkins Center for Point-of-Care Tests Research for Sexually Transmitted Disease (STDs), hereafter known as the Center, and serves as the technical lead for the Technology Development Core. The mission of the Center is to help companies accelerate their development and overcome/avoid potential hurdles that may arise.

2:30 Challenges in Translation of Biodosimetry Diagnostics to the Field

Mary Sproull, Biologist, Radiation Oncology Branch, National Institutes of Health (NIH/NCI/ROB)

This talk will cover the latest proteomic biodosimetry studies being conducted at the NCI, exploring dose prediction algorithms for both total body and partial body radiation exposures using animal models. Challenges in the development and translation of radiation diagnostics for field use will be highlighted.

3:00 POC Solutions for Women's Health

Sulatha Dwarakanath, PhD, CEO, Kaya17

3:30 Networking Break

FUNDING AND DEVELOPMENT OF BROADER POC PLATFORMS

3:45 HHS/ASPR/BARDA/DRIVE: Funding Innovations in at-Home and Point-of-Care Diagnostics

Kumar Subramanian, Senior Analyst & Subject Matter Expert, Medical Diagnostics, Tunnell Government Services

BARDA/DRIVE funds medical countermeasure development. This includes programs on diagnostics and decentralized healthcare technologies, host-based diagnostics, host-directed therapeutics, and healthcare infrastructure, implementation, and impact.

4:15 PANEL DISCUSSION: Overcoming the Obstacles to Developing Broader Diagnostic POC Platforms

Moderator: Harshini Mukundan, PhD, Scientist and Program Manager, Lawrence Berkeley National Laboratory; Senior Policy Advisor, The Council on Strategic Risks

Major technical challenges often prevent developers from producing new, broader point-of-care technology platforms that deliver the required clinical performance in a variety of settings. Barriers to adoption occur when decision makers do not understand the "value proposition" of new technologies. This panel

of experts will discuss how various approaches to technology development to deliver broad POC platforms can impact adoption and how next-generation technologies are being developed.

5:00 Close of Conference

SHORT COURSE*



Wednesday, June 7 | 6:00 – 7:30 pm

**Separate registration required.*



Short Course

SAMPLE PREP TECHNOLOGIES

This tutorial will discuss sample preparation technologies for detection, identification, and analysis of biomedical, biological, and chemical agents as well as biothreats in point-of-care, laboratory, and field settings. It will review the novel and rapid technologies for sample preparation, application of analytical strategies, and automation in biodetection.

SC1: Sample Prep Technologies

Instructors:

Dave Alburty, CEO, InnovaPrep

James Brayer, Associate Director, Market Development, Oxford Nanopore Technologies



SUBMIT A VIRTUAL POSTER FOR CONSIDERATION & SAVE \$50!



Cambridge Healthtech Institute encourages attendees to gain further exposure by presenting their work in the poster sessions. To ensure your virtual poster presentation is scheduled and included in the conference materials, your full submission must be received, and your registration paid in full by **May 5, 2023**.

Register and indicate that you would like to present a poster. Once your registration has been fully processed, we will send an email with a unique link and instructions for submitting your materials. Please see below for more information.

Reasons you should present your research poster at this conference:

- Your research will be seen by leaders from top commercial, academic, and government institutes
- Discuss your research and collaborate with other attendees
- Your poster title and short description will be published on our website
- Receive \$50 off your registration



BIODETECTION TECHNOLOGIES **VIRTUAL**



June 7-8, 2023 EDT [UT-4:00]

Special submission requirements for this event:

All scientific poster presentation materials will include:

- **Poster title**
- **Short text-only description for publication (70 word limit; about 500 characters)**
- **Short PowerPoint slideshow for on-screen sharing****

Virtual Poster Presentations will be held LIVE ONLINE.

***Your poster title and short description will be published on our website. We may collect and publish your poster presentation. For the LIVE ONLINE presentation, please prepare a short PowerPoint slideshow to display during the Poster Session. You will SHARE YOUR SCREEN and talk to attendees via video.*

Additional information:

- **Initial instructions with submission link are general and sent automatically. They will have slightly different requirements than what is needed for this event. Follow-up, conference-specific instructions will be sent.**
- **Please indicate your preferred poster program selection during submission. This detail is needed to assign and schedule the poster sessions.**
- **Presentation content should be scientific and relevant to the conference topic. Advertisements or solicitations will not be approved.**
- **Posters are limited to one per person.**

We reserve the right to publish your poster content in various marketing materials and products.

Poster inquiries: Email jring@cambridgeinnovationinstitute.com for details

PREMIUM REAL-TIME VIRTUAL PRICING - BEST VALUE

(Includes access to TWO conferences, Short Course, virtual event features, and On-Demand access for one year).

COMMERCIAL

ACADEMIC, GOVERNMENT, HOSPITAL-AFFILIATED

Early-Bird – Registration Rate until February 10, 2023	\$1199	\$699
Early – Registration Rate until March 17, 2023	\$1299	\$799
Advance – Registration Rate until May 5, 2023	\$1499	\$949
Standard – Registration Rate after May 5, 2023	\$1599	\$1099

STANDARD REAL-TIME VIRTUAL PRICING

(Includes access to ONE conference, virtual event features, and On-Demand access for one year. Excludes short course).

COMMERCIAL

ACADEMIC, GOVERNMENT, HOSPITAL-AFFILIATED

Early-Bird – Registration Rate until February 10, 2023	\$899	\$449
Early – Registration Rate until March 17, 2023	\$999	\$499
Advance – Registration Rate until May 5, 2023	\$1099	\$599
Standard – Registration Rate after May 5, 2023	\$1199	\$699

SHORT COURSE VIRTUAL PRICING

One Short Course	\$399	\$199
------------------	-------	-------

CONFERENCE DISCOUNTS*

- ☐ Alumni Discount: 20% off for both commercial and academics.
- ☐ Poster Discount: \$50 off for both commercial and academics.

Poster Submission - Discount (\$50 off): Poster materials are due by May 5, 2023. Once your registration has been fully processed, we will send an email containing a unique link and instructions for submitting your abstract and other materials. If you do not receive your link within 5 business days, please contact jring@healthtech.com.

Please see [website](#) for special poster requirements.

Virtual Event Group Pricing

Have your colleagues or entire team attend Biodetection Technologies.


Purchase a summit package at the individual/full price and participants from the same organization will receive a 25% discount when registering through the Group registration page.

For more information on group discounts, contact [Bill Mote](#) at 781-972-5479.

(Group registration package must be equal to or less than the value of the full price package.)

** Twitter, LinkedIn or any other promotional discounts cannot be combined. Discounts not applicable on event Short Courses.*

MEDIA PARTNERS



How to Register: **BiodetectionTechnologies.com**

reg@healthtech.com P: 781.972.5400 or Toll-free in the U.S. 888.999.6288

Please use keycode
2340F
when registering!